SELECTBIO has been given the great honour of hosting a workshop on Academic Drug Discovery at Buckingham House, Murray Edwards College, Cambridge University, UK.
Applying ever chaining models of partnership and technology transfer can be the most demanding of challenges facing any drug discovery project. The needs and requirements for each organisation involved can be so diverse, even when ultimately their goals are so similar. Bridging the gap between basic research and commercial application requires all parties to remain focused. With ever changing demands on global healthcare, pharmaceutical companies have been devolving their research activities to second and even third parties, thus diluting the high risk environment of drug discovery. This has created a great opportunity for academic and non- governmental organisations to transform their intellectual property into practical interventions that will more swiftly be of benefit in front line medicine.
This event will be the first of it’s kind in Europe, building on the success of our academic discovery events in the US and providing a platform for partnering in a global hub for life sciences research. It will attract participants who are currently open to partnering with academia, as well as those who are seeking to showcase their technical assets and expertise. There will be talks from industry service providers and stakeholders, universities and medical researchers, and pharmaceutical and biotechnology organisations from around the world. Looking forward to an era of drug discovery where cooperation and inter-organisational understanding enable revolutionary therapeutic innovation.
Agenda Topics:
• Drug discovery technology transfer
• European lead generation and enabling open innovation
• Novel approaches across different therapeutic areas
• Partnering models for academia and industry
• Professional translational research
Keynote Speakers:
- Stephen Frye
Director of The Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina
- Sir Tom Blundell
Group Leader, University of Cambridge
Hashtag - #add2015
Applying ever chaining models of partnership and technology transfer can be the most demanding of challenges facing any drug discovery project. The needs and requirements for each organisation involved can be so diverse, even when ultimately their goals are so similar. Bridging the gap between basic research and commercial application requires all parties to remain focused. With ever changing demands on global healthcare, pharmaceutical companies have been devolving their research activities to second and even third parties, thus diluting the high risk environment of drug discovery. This has created a great opportunity for academic and non- governmental organisations to transform their intellectual property into practical interventions that will more swiftly be of benefit in front line medicine.
This event will be the first of it’s kind in Europe, building on the success of our academic discovery events in the US and providing a platform for partnering in a global hub for life sciences research. It will attract participants who are currently open to partnering with academia, as well as those who are seeking to showcase their technical assets and expertise. There will be talks from industry service providers and stakeholders, universities and medical researchers, and pharmaceutical and biotechnology organisations from around the world. Looking forward to an era of drug discovery where cooperation and inter-organisational understanding enable revolutionary therapeutic innovation.
Agenda Topics:
• Drug discovery technology transfer
• European lead generation and enabling open innovation
• Novel approaches across different therapeutic areas
• Partnering models for academia and industry
• Professional translational research
Keynote Speakers:
- Stephen Frye
Director of The Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina
- Sir Tom Blundell
Group Leader, University of Cambridge
Hashtag - #add2015
